15353-j-veluchamy

90 | Chapter 3 29. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. : Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057, 2005. 30. Geller MA, Miller JS: Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 3:1445-1459, 2011. 31. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T et al. : Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 6:e20740, 2011. 32. Seidel UJ, Schlegel P, Lang P: Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 4:76, 2013. 33. Lehmann D, Spanholtz J, Osl M, Tordoir M, Lipnik K, Bilban M et al. : Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells. Stem Cells Dev 21:2926-2938, 2012. 34. Veluchamy JP, Lopez-Lastra S, Spanholtz J, Bohme F, Kok N, Heideman DA et al. : In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Front Immunol. 2017 Feb 6;8:87. 35. Koopman LA, Szuhai K, van Eendenburg JD, Bezrookove V, Kenter GG, Schuuring E et al. : Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res 59:5615-5624, 1999. 36. Heideman DA, Thunnissen FB, Doeleman M, Kramer D, Verheul HM, Smit EF et al. : A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol 31:329-333, 2009. 37. Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA et al. : KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn 14:247-255, 2012. 38. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I et al. : High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One 5:e9221, 2010. 39. Campbell KS, Hasegawa J: Natural killer cell biology: an update and future directions. J Allergy Clin Immunol 132:536-544, 2013. 40. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8:299-308, 2008. 41. Wang M, Yin B, Wang HY, Wang RF: Current advances in T-cell-based cancer immunotherapy. Immunotherapy 6:1265-1278, 2014. 42. Rezvani K, Rouce RH: The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Front Immunol 6:578, 2015. 43. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR et al. : Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted